The importance of xCT as a druggable oncology target
AgilVax is also developing a monoclonal antibody-based therapy (xCT-mAb) to target xCT. xCT-mAb was developed following the identification and characterization of antibodies produced from immunization with AX09. In preclinical testing xCT-mAb has demonstrated great promise as a potential therapeutic candidate. We are currently evaluating xCT-mAb in both in-vitro and in-vivo oncology models.